The company has successfully implemented the ABioC tissue engineering in situ regeneration technology in the treatment of sports system injuries

With the construction of innovative provinces and the in-depth implementation of the innovation-driven development strategy in Zhejiang, a large number of technology-based small and medium-sized enterprises have sprung up like mushrooms in the region. Zhejiang Xingyue Biotechnology Co., Ltd. is located in "Hangzhou Future Science and Technology City", known as the "Silicon Valley of the East". In 2011, it was approved by the Provincial Science and Technology Department to jointly establish the Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine Technology with Zhejiang University. Relying on the provincial key laboratory, Xingyue Biotechnology has independently developed a new tissue engineering technology - ABioCTM technology, providing a new regenerative medicine technology for the treatment of sports system injuries.

What exactly is ABioCTM treatment technology and its advantages? ABioC, fully known as Autologous Bioactive Concentrates (ABioCTM), utilizes serum extracted from one's own blood, rich in high concentrations of growth factors, for treatment. It can enhance the healing quality of various tissue injuries, boasting advantages such as being autologous, simple to prepare, non-toxic, and highly safe. Once activated, the autologous bioactive concentrates can release multiple growth factors, at concentrations 3-8 times higher than normal levels in the body. The ratio of various growth factors closely resembles the normal physiological concentration in the body, enabling optimal synergistic effects among the growth factors and promoting tissue healing and regeneration.

The ABioCTM treatment technology also boasts significant characteristics such as remarkable therapeutic effects, no immune rejection, allergic reactions, or other side effects, short treatment time, non-invasive, painless, no bleeding, no recovery period, and no impact on normal work and life. This technology has a wide range of applications and can be used for the treatment of non-union or delayed union of fractures, as well as conditions such as tissue defects, degenerative knee joint lesions, chronic Achilles tendon lesions, muscle injuries, and ligament injuries.

Currently, the ABioCTM treatment technology has been effectively applied in the sports medicine community within the province, successfully curing multiple athletes with non-union fractures. Postoperative follow-up results indicate that after using the ABioCTM treatment technology, athletes' symptoms of pain and swelling have significantly alleviated. Furthermore, some athletes returned to normal training and competition after just 3 weeks of treatment, extending their careers and allowing them to return to the field. At the same time, Xingyue Biotechnology has promoted this technology outside Zhejiang Province, collaborating with multiple orthopedic hospitals outside the province and achieving excellent treatment results. We believe that the promotion of ABioCTM treatment technology will benefit the development of sports in Zhejiang Province and even the entire country, bringing good news to the vast number of patients with intractable sports injuries.